Pulmonx Corp. (LUNG) is scheduled to release financial results for the first quarter of 2025 after the close of trading today.
The company is a provider of minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease, and its marketed products include Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, and LungTraX Platform (which is called the StratX Platform in international markets).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com